UCB Acquires Belgian Gene Therapy Firm Handl
Also Inks Deal With Lacerta
Executive Summary
The Brussels-based company has leant on its local knowledge to snap up Leuven-headquartered biotech Handl and its proprietary AAV capsid technology platform.
You may also be interested in...
Deal Watch: Lilly Finds New Partners For Genetic Disorders, Protein Degradation
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
UCB Acquires Engage To Boost Epilepsy Franchise
The Belgian drugmaker is getting hold of a device that delivers an inhaled formulation of the anxiety drug alprazolam which can rapidly terminate an epileptic seizure 30 seconds after it has begun.
UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears
The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.